Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL6547534 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1125864 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL302681 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL419844 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL3097543 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL418934 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1429909 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| D-Proline SCHEMBL18493080 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1675389 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1895918 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047716-A1 | SARS-COV-2 VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2026-03-05 | — | — | WO | claimed |
| EP-4642481-A2 | MULTITARGET VACCINES AND THERAPEUTICS | Popvax Private Limited (IN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025088052-A1 | CYCLIC ANALOGUE OF GLYCINE-PROLINE FOR USE IN THE PREVENTION AND/OR TREATMENT OF MEDICAL IMPLANT-RELATED FIBROSIS | ROUSSELOT BV (BE) | 2025-05-01 | — | — | WO | claimed |
| CN-119855584-A | Formulations comprising anti-Claudin18.2 and CD3 bispecific antibodies, methods of making and uses thereof | 信达生物制药(苏州)有限公司 | 2025-04-18 | — | — | CN | claimed |
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | claimed |
| CN-118240791-A | Glycosyltransferase mutant and application thereof in Reb D synthesis | 百开盛(上海)生物科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117820232-A | Non-covalent dimer cations, salts thereof, preparation method thereof and antioxidation application thereof | 苏州质子链生物技术有限公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2023185732-A1 | PREPARATIONS CONTAINING ANTI-CLAUDIN18.2/CD3 BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF | 信达生物制药（新加坡）有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-116077646-A | Antibody preparation for resisting coronavirus S protein, preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-114146174-A | anti-PD-L1/OX 40 bispecific antibody preparation and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2022-03-08 | — | — | CN | claimed |
| US-7781567-B2 | Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides | NPS PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | claimed |
| EP-2161279-A1 | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies | Centre National de la Recherche Scientifique (FR) | 2010-03-10 | — | — | EP | claimed |
| WO-2010023247-A1 | SYNTHETIC PEPTIDES CORRESPONDING TO OVERLAPPING NEUTRALIZING DETERMINANTS IN THE CBD1 EPITOPE INDUCE BROADLY NEUTRALIZING ANTIBODIES. | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-03-04 | — | — | WO | claimed |
| EP-1572720-A4 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2-(1-34) PEPTIDES | NPS ALLELIX CORP (CA) | 2008-12-24 | — | — | EP | claimed |
| US-20060024778-A1 | Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides | NPS PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | claimed |
| EP-1572720-A2 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2-(1-34) PEPTIDES | NPS Allelix Corp. (CA) | 2005-09-14 | — | — | EP | claimed |
| WO-2003099854-A2 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2-(1-34) PEPTIDES | NPS ALLELIX CORP. (CA) | 2003-12-04 | — | — | WO | claimed |
| EP-0210257-A4 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. | HURWITZ CHARLES (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0210257-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ, Charles (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004588-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ CHARLES (US) | 1986-08-14 | — | — | WO | claimed |